Abstract: Systems and techniques are provided for compressing data. A process can include generating a compressed sub-packet by removing one or more sparsity bytes from a sequence of values corresponding to a sub-packet, the sequence of values including one or more sparsity bytes each equal to a configured sparsity value and one or more non-sparsity bytes each corresponding to a respective data value different from the configured sparsity value. A sub-packet header can be generated for the compressed sub-packet, and indicative of a respective location within the sequence of values of each non-sparsity byte. A packet header can be generated for a plurality of compressed sub-packets, and indicative of the configured sparsity value and respective coding information for each compressed sub-packet. A compressed data packet can be generated to include at least the packet header, the sub-packet header, and the one or more non-sparsity bytes included in the sequence of values.

Abstract: A light control film includes opposing substantially planar substantially parallel first and second major surfaces spaced apart along a thickness direction of the light control film by less than about 500 microns; and a plurality of substantially parallel optically transparent polymeric columns disposed in, and substantially surrounded by, a light absorbing polymeric material. Each of the polymeric columns has a first column end at the first major surface and an opposite second column end at the second major surface and has an aspect ratio of greater than about 3, such that the first column ends of at least one pair of adjacent polymeric columns include substantially parallel substantially straight sides facing, and substantially coextensive with, each other.

Abstract: A bond pad with micro-protrusions for direct metallic bonding. In one embodiment, a semiconductor device comprises a semiconductor substrate, a through-silicon via (TSV) extending through the semiconductor substrate, and a copper pad electrically connected to the TSV and having a coupling side. The semiconductor device further includes a copper element that projects away from the coupling side of the copper pad. In another embodiment, a bonded semiconductor assembly comprises a first semiconductor substrate with a first TSV and a first copper pad electrically coupled to the first TSV, wherein the first copper pad has a first coupling side. The bonded semiconductor assembly further comprises a second semiconductor substrate, opposite to the first semiconductor substrate, the second semiconductor substrate comprising a second copper pad having a second coupling side. A plurality of copper connecting elements extend between the first and second coupling sides of the first and second copper pads.

Abstract: A driving assembly includes a main control chip, a circuit selection chipset and a channel chipset. The circuit selection chipset includes more than one circuit selection chip used to be electrically connected with each light source voltage line in one-to-one correspondence, and is configured to enable each circuit selection chip to load the light source voltage to the connected light source voltage line one by one under control of the main control chip; the channel chipset includes more than one channel control chip, each channel control chip is used to be electrically connected with one or more channel lines; the channel chipset is configured to enable the channel control chip to control driving current on each connected channel line under control of the main control chip.

Abstract: The present invention belongs to the field of medicine, and relates to use of cannabidiol (CBD) in the treatment of pulmonary arterial hypertension. The CBD can be used as the only active ingredient or combined with other active ingredients to prepare a medicament for treating pulmonary arterial hypertension. Specifically, the present invention relates to use of any one selected from (1) to (3) in the preparation of a medicament for treating and/or preventing pulmonary arterial hypertension: (1) CBD, (2) a plant extract containing the CBD; and preferably, the plant extract is a cannabis extract, and (3) a pharmaceutical composition containing the CBD and one or more pharmaceutically acceptable adjuvants. In the present invention, upon experimental researches, it has found that the CBD has the function of inhibiting pulmonary arterial hypertension, and is especially suitable for treating the pulmonary arterial hypertension caused by hypoxemia.

Abstract: The present invention belongs to the field of medicine, and relates to use of cannabidiol (CBD) in the treatment of pulmonary arterial hypertension. The CBD can be used as the only active ingredient or combined with other active ingredients to prepare a medicament for treating pulmonary arterial hypertension. Specifically, the present invention relates to use of any one selected from (1) to (3) in the preparation of a medicament for treating and/or preventing pulmonary arterial hypertension: (1) CBD, (2) a plant extract containing the CBD; and preferably, the plant extract is a cannabis extract, and (3) a pharmaceutical composition containing the CBD and one or more pharmaceutically acceptable adjuvants. In the present invention, upon experimental researches, it has found that the CBD has the function of inhibiting pulmonary arterial hypertension, and is especially suitable for treating the pulmonary arterial hypertension caused by hypoxemia.

Abstract: An automatic carton forming device includes a supporting table, a storage rack, a limiting part, a transporting part, and a folding part. The storage rack is configured to store folded paper boards, the limiting part is configured to limit the folded paper boards, the transporting part includes a moving base and a driving unit for driving the moving base to move. At least one first vacuum suction cup is disposed on the moving base, the limiting part includes an adsorbing base disposed on one end of the supporting table, at least one second vacuum suction cup is disposed on the adsorbing base. The folding part includes a first overturning plate, a vertical folding unit, a transverse folding unit, and a transmitting unit, and the transmitting unit drives the first overturning plate, the vertical folding unit, and the transverse folding unit to perform folding action.

Abstract: The present disclosure relates to a composite membrane and a packaging structure. The composite membrane comprises: a carrier layer; and an information layer, wherein the information layer is disposed on one side of the carrier layer along thickness direction of the composite membrane, and the information layer further comprises a light-transmitting layer, a first pattern layer, and a second pattern layer, which are disposed along the thickness direction of the composite membrane, wherein: the first pattern layer is disposed close to the carrier layer; the light-transmitting layer is disposed on one side of the first pattern facing layer away from the carrier layer; the second pattern layer is disposed on one side of the light-transmitting layer facing away from the carrier layer, and the second pattern layer and the first pattern layer present different visual information of one multi-dimensional object.

Abstract: The present invention belongs to the field of medicine, and relates to use of cannabidiol (CBD) in the treatment of pulmonary arterial hypertension. The CBD can be used as the only active ingredient or combined with other active ingredients to prepare a medicament for treating pulmonary arterial hypertension. Specifically, the present invention relates to use of any one selected from (1) to (3) in the preparation of a medicament for treating and/or preventing pulmonary arterial hypertension: (1) CBD, (2) a plant extract containing the CBD; and preferably, the plant extract is a cannabis extract, and (3) a pharmaceutical composition containing the CBD and one or more pharmaceutically acceptable adjuvants. In the present invention, upon experimental researches, it has found that the CBD has the function of inhibiting pulmonary arterial hypertension, and is especially suitable for treating the pulmonary arterial hypertension caused by hypoxemia.

Abstract: A terminal functional side chain-substituted diketopyrrolopyrrole (DPP)-based terpolymer and a preparation method and use thereof is described herein. The terpolymer has the following structural formula: where R1 is a terminal siloxy-substituted swallow-tailed chain with 22 to 52 carbon atoms in total, and t1 and t2 each are an integer of 1 to 18; R2 is a semifluoroalkyl-substituted swallow-tailed chain with 12 to 60 carbon atoms in total and 10 to 46 fluorine atoms in total, t3 and t4 each are an integer of 1 to 16, and t5 and t6 each are an integer of 1 to 10; and Ar is any one selected from the group consisting of aryl, heteroaryl, substituent-containing aryl, and substituent-containing heteroaryl, and m and n each are an integer of 5 to 100.

Abstract: The present disclosure relates to a composite membrane and a packaging structure. The composite membrane comprises: a carrier layer; and an information layer, wherein the information layer is disposed on one side of the carrier layer along thickness direction of the composite membrane, and the information layer further comprises a light-transmitting layer, a first pattern layer, and a second pattern layer, which are disposed along the thickness direction of the composite membrane, wherein: the first pattern layer is disposed close to the carrier layer; the light-transmitting layer is disposed on one side of the first pattern facing layer away from the carrier layer; the second pattern layer is disposed on one side of the light-transmitting layer facing away from the carrier layer, and the second pattern layer and the first pattern layer present different visual information of one multi-dimensional object.

Abstract: The present invention belongs to the field of biomedicine and relates to use of cannabidiol in the preparation of anti-influenza drugs. Specifically, the present invention relates to use of any one of (1) to (3) below in the preparation of drugs for treating or preventing influenza or drugs for relieving an influenza symptom: (1) cannabidiol or a pharmaceutically acceptable salt or ester thereof; (2) a plant extract containing cannabidiol; preferably, a cannabis extract containing cannabidiol; preferably, an industrial cannabis extract containing cannabidiol; and (3) a pharmaceutical composition, containing an effective amount of cannabidiol or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable auxiliary materials. The cannabidiol can effectively inhibit influenza viruses, and has the potential to prepare or be used as a drug for treating or preventing influenza.

Abstract: The present invention belongs to the field of medicine, and relates to use of cannflavin A in preparation of a drug for promoting wound healing. Particularly, the present invention relates to use of cannflavin A in preparation of a drug for promoting wound healing of type II diabetes. Cannflavin A can effectively promote wound healing, and has the potential to prepare a drug for promoting wound healing, especially for preventing and treating diabetic feet.

Abstract: The present invention discloses a composition for preventing and/or treating woman dysmenorrhea; the composition includes cannabidiol and/or cannabidivarol, a penetration enhancer as well as a carrier; the mass ratio of the cannabidiol and/or the cannabidivarol to the penetration enhancer is 1:(0.1-0.8). The composition provided by the present invention can effectively relieve woman dysmenorrhea, and solve the problem of lackness of a composition of cannabidiol and/or cannabidivarol which can effectively prevent and/or treat woman dysmenorrhea in the prior art. Meanwhile, the composition provided by the present invention can also be used in preparation of a feminine hygiene product for preventing and/or treating woman dysmenorrhea.

Abstract: An information handling system may include a processor and a program of instructions embodied on non-transitory computer readable media, the instructions, when read and executed, for causing the processor to perform integrity verification of a secondary firmware image that serves as a backup to a primary firmware image of an information handling resource by performing a plurality of individual integrity verifications wherein each of the plurality of individual integrity verifications is performed on a respective portion of the secondary firmware image in a manner that minimizes a boot time for the information handling system and determining that integrity verification of the secondary firmware image failed and initiating recovery of the secondary firmware image if one of the plurality of individual integrity verifications fails.

Abstract: A system for sequencing firmware updates comprising a sequenced payload creation system operating on a processor and configured to receive two or more firmware payload sets and to generate a payload sequence for the two or more firmware payload sets. A BIOS payload system operating on the processor and configured to receive the two or more firmware payload sets and the payload sequence and to generate a basic input/output system (BIOS) payload. A BIOS locking system operating on the processor and configured to receive the BIOS payload and to generate a secure BIOS executable.

Abstract: A system for sequencing firmware updates comprising a sequenced payload creation system operating on a processor and configured to receive two or more firmware payload sets and to generate a payload sequence for the two or more firmware payload sets. A BIOS payload system operating on the processor and configured to receive the two or more firmware payload sets and the payload sequence and to generate a basic input/output system (BIOS) payload. A BIOS locking system operating on the processor and configured to receive the BIOS payload and to generate a secure BIOS executable.

Abstract: The invention provides a composition comprising cannabidiol or a cannabis extract, and caffein. The mass percentage of the cannabidiol in the cannabis extract is 10%-99%. A mass ratio of the cannabidiol to the caffein in the composition is (1-100):60. The composition can be a food composition or a pharmaceutical composition. The cannabidiol or the cannabis extract can prevent and/or ameliorate adverse reactions induced by the caffeine, and in particular, prevent and/or ameliorate anxiety behaviors induced by the caffeine.

Abstract: The present invention belongs to the field of biomedicine and relates to use of cannabidiol in the preparation of anti-influenza drugs. Specifically, the present invention relates to use of any one of (1) to (3) below in the preparation of drugs for treating or preventing influenza or drugs for relieving an influenza symptom: (1) cannabidiol or a pharmaceutically acceptable salt or ester thereof; (2) a plant extract containing cannabidiol; preferably, a cannabis extract containing cannabidiol; preferably, an industrial cannabis extract containing cannabidiol; and (3) a pharmaceutical composition, containing an effective amount of cannabidiol or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable auxiliary materials. The cannabidiol can effectively inhibit influenza viruses, and has the potential to prepare or be used as a drug for treating or preventing influenza.

Abstract: The present invention belongs to the field of medicaments and daily chemicals, and relates to use of cannabidiol or an cannabis extract in preparing a skin whitening product. Particularly, the present invention relates to use of any one of (1) to (2) below in preparing a drug or a reagent for inhibiting tyrosinase activity, inhibiting melanin formation or inhibiting melanocyte generation: (1) cannabidiol or a pharmaceutically acceptable salt or ester thereof; and (2) a plant extract containing cannabidiol. The cannabidiol or the cannabis extract can effectively inhibit activity of tyrosinase, and has a good skin whitening effect.